中文版 | English


Alternative Title
Name pinyin
DENG Limin
School number
0710 生物学
Subject category of dissertation
07 理学
Mentor unit
Publication Years
Submission date
Place of Publication


Other Abstract

Ovarian cancer and breast cancer represent two kinds of malignant tumors which seriously threat women's health and bring a huge burden to the patients. Due to the large population in China, the patient numbers and deaths of ovarian and breast cancers are among the highest in the world. In-depth study of molecular mechanisms underlying ovarian and breast tumor development is helpful to the diagnosis, treatment, and prognosis of relevant tumor patients. It has been reported that long non-coding RNAs lncRNAs play an extremely important role in a wide-range of cancers. Our lab previously reported a novel LncRNA LOC100288181, named as Lnc-OC1 in ovarian cancer. Lnc-OC1 promotes the proliferation and migration of ovarian cancer cells by sponging miR-34a/miR-34c. In this study, a primary culture named Sample1 was established from patient ascites and was used to test Lnc-OC1 function. Immunofluorescence staining and flow cytometry analysis demonstrated that the primary culture had the properties of epithelial cancer cells. A series of functional in vitro and in vivo experiments demonstrated that knockdown of Lnc-OC1 significantly inhibited cell proliferation, cell migration, and cell invasion, while promoting apoptosis. Tumorigenesis experiment showed that knockdown of Lnc-OC1 inhibited tumor growth. In addition, preliminary study suggests that Lnc-OC1 is not involved in the resistance of ovarian cancer cells to carboplatin or paclitaxel. In breast cancer cell line MDA-MB-231, knockdown of Lnc-OC1 could suppress the cell proliferation, cell spheroid capacity and stem cell ratio. These results suggest that Lnc-OC1 promotes the growth of ovarian and breast cancers, playing an oncogenic role.

Training classes
Enrollment Year
Year of Degree Awarded
References List

[1]Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review[J]. Seminars in Oncology Nursing, 2019, 35(2): 151-156.
[2] Loibl S, Poortmans P, Morrow M, et al. Breast cancer[J]. Lancet, 2021, 397(10286): 1750-1769.
[3] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022[J]. Ca-a Cancer Journal for Clinicians, 2022, 72(1): 7-33.
[4] Chen V W, Ruiz B, Killeen J L, et al. Pathology and classification of ovarian tumors[J]. Cancer, 2003, 97(10): 2631-+.
[5] Jo V Y, Fletcher C D M. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition[J]. Pathology, 2014, 46(2): 95-104.
[6] Vang R, Shih I M, Kurman R J. Ovarian Low-grade and High-grade Serous Carcinoma Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems[J]. Advances in Anatomic Pathology, 2009, 16(5): 267-282.
[7] Villert A B, Kolomiets L A, Yunusova N V, et al. Ascites as a subject of studies in ovarian cancer[J]. Sibirskii onkologicheskii zhurnal, 2019, 18(1): 116-123.
[8] Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253.
[9] Sun L-X, Wu Y, Han H-Q, et al. Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma[J]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, 22(1): 58-61.
[10]Lahlou N, Brun J L. Ovarian tumor markers of presumed benign ovarian tumors[J]. Journal De Gynecologie Obstetrique Et Biologie De La Reproduction, 2013, 42(8): 752-759.
[11]Bhardwaj B K, Thankachan S, Venkatesh T, et al. Liquid biopsy in ovarian cancer[J]. Clinica Chimica Acta, 2020, 510: 28-34.
[12]Dumontet C, Sikic B J J O C O O J O T a S O C O. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death[J]. 1999, 17(3): 1061-1070.
[13]Mosca L, Ilari A, Fazi F, et al. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming[J]. Drug Resistance Updates, 2021, 54.
[14]Haldar S, Basu A, Croce C J C R. Bcl2 is the guardian of microtubule integrity[J]. 1997, 57(2): 229-233.
[15]Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group[J]. 1998, 78(11): 1479-1487.
[16]Dijt F, Fichtinger-Schepman A, Berends F, et al. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts[J]. 1988, 48(21): 6058-6062.
[17]Perez R J E J O C. Cellular and molecular determinants of cisplatin resistance[J]. 1998, 34(10): 1535-1542.
[18]Cortez A J, Tudrej P, Kujawa K A, et al. Advances in ovarian cancer therapy[J]. Cancer Chemotherapy and Pharmacology, 2018, 81(1): 17-38.
[19]Chester C, Dorigo O, Berek J S, et al. Immunotherapeutic approaches to ovarian cancer treatment[J]. Journal for ImmunoTherapy of Cancer, 2015, 3(1): 7.
[20]Wicki A, Witzigmann D, Balasubramanian V, et al. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications[J]. Journal of Controlled Release, 2015, 200: 138-157.
[21]Sharma S, Walsh D. Management of symptomatic malignant ascites with diuretics: Two case reports and a review of the literature[J]. Journal of Pain and Symptom Management, 1995, 10(3): 237-242.
[22]Adam R A, Adam Y G. Malignant ascites: past, present, and future[J]. Journal of the American College of Surgeons, 2004, 198(6): 999-1011.
[23]Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review[J]. Investigational New Drugs, 2010, 28(6): 887-894.
[24]Ba M, Long H, Zhang X, et al. Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites[J]. Journal of Cancer Research and Clinical Oncology, 2014, 140(9): 1497-1506.
[25]Giuntoli R L, Ii, Webb T J, Zoso A, et al. Ovarian Cancer-associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity[J]. Anticancer Research, 2009, 29(8): 2875-2884.
[26]Bamias A, Tsiatas M L, Kafantari E, et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3(+)CD56(+) cells with platinum resistance[J]. Gynecologic Oncology, 2007, 106(1): 75-81.
[27]Shi Y, Hao M, Ding Z. Study on ascite of ovarian cancer[J]. Zhonghua fu chan ke za zhi, 2000, 35(9): 551-553.
[28]Connor J P, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance[J]. Gynecologic Oncology, 2008, 111(2): 330-335.
[29]Cohen M, Pierredon S, Wuillemin C, et al. Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells[J]. Oncoscience, 2014, 1(4): 262-271.
[30] Desantis C, Ma J M, Bryan L, et al. Breast Cancer Statistics, 2013[J]. Ca-a Cancer Journal for Clinicians, 2014, 64(1): 52-62.
[31] Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chinese Medical Journal, 2021, 134(7): 783-791.
[32] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical Journal, 2022.
[33] Wang Y-J, Wang F, Yu L-X, et al. Worldwide review with meta-analysis of women's awareness about breast cancer[J]. Patient education and counseling, 2021.
[34] Kuchenbaecker K B, Hopper J L, Barnes D R, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA - Journal of the American Medical Association, 2017, 317(23): 2402-2416.
[35] Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women[J]. New England Journal of Medicine, 2021, 384(5): 428-439.
[36] Nur U, El Reda D, Hashim D, et al. A prospective investigation of oral contraceptive use and breast cancer mortality: Findings from the Swedish women's lifestyle and health cohort[J]. BMC Cancer, 2019, 19(1).
[37] O'sullivan C C, Loprinzi C L, Haddad T C. Updates in the Evaluation and Management of Breast Cancer[J]. Mayo Clinic Proceedings, 2018, 93(6): 794-807.
[38] Wagner J, Rapsomaniki M A, Chevrier S, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer[J]. Cell, 2019, 177(5): 1330-1345 e1318.
[39] 涂强. lncRNAs在三阴性乳腺癌发生发展中的作用[J]. 医学信息, 2020, 33(10):3.
[40] 甘凤娇. 长链非编码RNA在乳腺癌中的研究进展[J]. 现代肿瘤医学, , 2020, 28(23):4.
[41] 郝杰. 长链非编码RNA与乳腺癌关系的研究进展[J]. 现代肿瘤医学, 2020, 28(6):4.
[42] Von Minckwitz G, Huang C S, Mano M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. New England Journal of Medicine, 2019, 380(7): 617-628.
[43] Gao J J, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis[J]. The Lancet Oncology, 2020, 21(2): 250-260.
[44] Ponting C P, Oliver P L, Reik W. Evolution and Functions of Long Noncoding RNAs[J]. Cell, 2009, 136(4): 629-641.
[45] Rinn J L, Chang H Y. Genome Regulation by Long Noncoding RNAs[M]. // KORNBERG R D. Annual Review of Biochemistry, Vol 81. City, 2012: 145-166. ://WOS:000305765500008.
[46] Salmena L, Poliseno L, Tay Y, et al. A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?[J]. Cell, 2011, 146(3): 353-358.
[47] Huang J Z, Chen M, Chen D, et al. A Peptide Encoded by a Putative lncRNA HOXB-AS3 Suppresses Colon Cancer Growth[J]. Molecular Cell, 2017, 68(1): 171-+.
[48] 汪显坤. 长链非编码RNA及其与人类疾病之间关系的研究概述[J]. 生物学教学, 2019.
[49] Wang J C, Su Z L, Lu S N, et al. LncRNA HOXA-AS2 and its molecular mechanisms in human cancer[J]. Clinica Chimica Acta, 2018, 485: 229-233.
[50] Gupta R A, Shah N, Wang K C, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J]. Nature, 2010, 464(7291): 1071-U1148.
[51] Gutschner T, Haemmerle M, Diederichs S. MALAT1- a paradigm for long noncoding RNA function in cancer[J]. Journal of Molecular Medicine-Jmm, 2013, 91(7): 791-801.
[52] Huang J, Zhou N, Watabe K, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1)[J]. Cell Death & Disease, 2014, 5.
[53] Liu S S, Du Q Y, Rao Y, et al. Long non-coding RNA NPBWR1-2 affects the development of ovarian cancer via multiple microRNAs[J]. Oncology Letters, 2020, 20(1): 685-692.
[54] Yuan D L, Zhang X F, Zhao Y L, et al. Role of lncRNA-ATB in ovarian cancer and its mechanisms of action[J]. Experimental and Therapeutic Medicine, 2020, 19(2): 965-971.
[55] Mao T L, Fan M H, Dlamini N, et al. LncRNA MALAT1 Facilitates Ovarian Cancer Progression through Promoting Chemoresistance and Invasiveness in the Tumor Microenvironment[J]. International Journal of Molecular Sciences, 2021, 22(19).
[56] Tao F, Tian X, Lu M, et al. A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c[J]. Journal of Genetics and Genomics, 2018, 45(3): 137-145.
[57] Wu G, Yang Z, Chen Y, et al. Downregulation of Lnc-OC1 attenuates the pathogenesis of polycystic ovary syndrome[J]. Molecular and Cellular Endocrinology, 2020, 506.
[58] Liu Y, Chang Y, Cai Y-X. Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma[J]. Reproductive Sciences, 2020, 27(10): 1848-1856.
[59] Mohammadzadeh A, Baradaran B, Dastmalchi N, et al. The Correlation Between Helicobacter pylori Infection and Lnc-OC1 Expression in Gastric Cancer Tissues in an Iranian Population[J]. Journal of gastrointestinal cancer, 2021, 52(2): 600-605.
[60] Morlando M, Ballarino M, Fatica A. Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia[J]. Frontiers in medicine, 2015, 2: 23.
[61] 关玉盘. 恶性腹水的诊断与鉴别诊断[J]. 中国消化内镜, 2007(10):6.
[62] Woopen H, Sehouli J. Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer[J]. Anticancer Research, 2009, 29(8): 3353-3359.
[63] Scarberry K E, Dickerson E B, Zhang Z J, et al. Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles[J]. Nanomedicine-Nanotechnology Biology and Medicine, 2010, 6(3): 399-408.
[64] 邢宝玲, 郭存存, 唐正华,等. 分选卵巢癌腹水中癌细胞的实验研究[J]. 中国现代医学杂志, 2018, 28(17):7.
[65] Patriarca C, Macchi R M, Marschner A K, et al. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review[J]. Cancer Treatment Reviews, 2012, 38(1): 68-75.
[66] Janku F, Tsimberidou A M, Garrido-Laguna I, et al. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors[J]. Molecular Cancer Therapeutics, 2011, 10(3): 558-565.
[67] Ma N N, Li S R, Zhang Q H, et al. Long non-coding RNA GAS5 inhibits ovarian cancer cell proliferation via the control of microRNA-21 and SPRY2 expression[J]. Experimental and Therapeutic Medicine, 2018, 16(1): 73-82.
[68] Yu Y, Zhang X H, Tian H S, et al. Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy[J]. Journal of Buon, 2018, 23(5): 1396-1401.
[69] Wen A P, Luo L, Du C C, et al. Long non-coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA-155-5p/tyrosinase-related protein 1 axis[J]. Experimental and Therapeutic Medicine, 2021, 22(5).
[70] Puiffe M-L, Le Page C, Filali-Mouhim A, et al. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer[J]. Neoplasia, 2007, 9(10): 820-U834.
[71] Meunier L, Puiffe M-L, Le Page C, et al. Effect of Ovarian Cancer Ascites on Cell Migration and Gene Expression in an Epithelial Ovarian Cancer In Vitro Model[J]. Translational Oncology, 2010, 3(4): 230-238.
[72] Matei D, Fang F, Shen C Y, et al. Epigenetic Resensitization to Platinum in Ovarian Cancer[J]. Cancer Research, 2012, 72(9): 2197-2205.
[73] Mcauliffe S M, Morgan S L, Wyant G A, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(43): E2939-E2948.
[74] Dong Y J, Feng W, Li Y. HOTTIP-miR-205-ZEB2 Axis Confers Cisplatin Resistance to Ovarian Cancer Cells[J]. Frontiers in Cell and Developmental Biology, 2021, 9.
[75] Tian X Y, Zuo X H, Hou M, et al. LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3[J]. Journal of Cancer, 2021, 12(19): 5712-5722.
[76] Huang B, Wei M, Hong L. Long noncoding RNA HULC contributes to paclitaxel resistance in ovarian cancer via miR-137/ITGB8 axis[J]. Open Life Sciences, 2021, 16(1): 667-681.
[77] Liu S W, Zou B Y, Tian T, et al. Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway[J]. Journal of Cellular Biochemistry, 2019, 120(5): 7581-7589.
[78]Zhao Y Z, Hong L. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-kappa B Signaling Pathway[J]. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36(2): 202-210.
[79] Kim J, Piao H L, Kim B J, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis[J]. Nature Genetics, 2018, 50(12): 1705-+.
[80] Liang Y R, Song X J, Li Y M, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis[J]. Molecular Cancer, 2020, 19(1).
[81] Zhao W Y, Geng D H, Li S Q, et al. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer[J]. Cancer Medicine, 2018, 7(3): 842-855.
[82] Zhu P P, He F, Hou Y X, et al. A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability[J]. Oncogene, 2021, 40(9): 1609-1627.
[83] Liang J, Li Y, Daniels G, et al. LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a[J]. Molecular Cancer Research, 2015, 13(4): 681-688.
[84] Fang L-L, Sun B-F, Huang L-R, et al. Potent Inhibition of miR-34b on Migration and Invasion in Metastatic Prostate Cancer Cells by Regulating the TGF-beta Pathway[J]. International Journal of Molecular Sciences, 2017, 18(12).
[85] Tomasi M L, Cossu C, Spissu Y, et al. S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis[J]. Oncotarget, 2017, 8(45): 78851-78869.
[86] Park E Y, Chang E, Lee E J, et al. Targeting of miR34a-NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance[J]. Cancer Research, 2014, 74(24): 7573-7582.

Academic Degree Assessment Sub committee
Domestic book classification number
Data Source
Document TypeThesis
DepartmentSchool of Medicine
Recommended Citation
GB/T 7714
邓丽敏. Lnc-OC1在卵巢癌和乳腺癌中的功能探究[D]. 深圳. 南方科技大学,2022.
Files in This Item:
File Name/Size DocType Version Access License
11930136-邓丽敏-南方科技大学医(10503KB) Restricted Access--Fulltext Requests
Related Services
Fulltext link
Recommend this item
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[邓丽敏]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[邓丽敏]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[邓丽敏]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.